Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence there. Traditionally, patients suffering from MS in China have been treated with two disease-modifying therapies (DMTs)—IFN-β-1b (Bayer’s Betaferon) and teriflunomide (Sanofi’s Aubagio)—and immunosuppressants such as methotrexate, mitoxantrone, rituximab, and azathioprine. The National Medical Products Administration is focused on granting fast-track designation to new therapies that address urgent clinical need in China, thus allowing such agents to move directly to the market-filing stage based on foreign clinical trial data, especially in the case of rare diseases. Recent inclusions of two S1PR modulators—fingolimod (Novartis’s Gilenya) and siponimod (Novartis’s Mayzent)—in the 2020 National Reimbursement Drug List will drive the uptake of these agents for MS in China, thus boosting overall market sales.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys of 50 neurologists.
Diagnosed prevalence of MS by country, with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key MS therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 2+ drugs; Phase II: 2 drugs; coverage of select preclinical and Phase I products.